Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28152781 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL16696528 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL13745287 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL2059625 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL2059641 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL3792192 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL13753761 | 1.00 | PYGB (0.78) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL21302832 | 0.99 | PYGB (0.76) | PYGBGAAEPHX2TRPV1CNR1 | |
| SCHEMBL8669655 | 0.93 | PYGB (0.74) | PYGBGAAEPHX2PRKCAAKT1 | |
| SCHEMBL8665848 | 0.93 | PYGB (0.74) | PYGBGAAEPHX2PRKCAAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114209651-A | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof | 上海欣峰制药有限公司 | 2022-03-22 | — | — | CN | claimed |
| CN-114053226-A | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof | 上海欣峰制药有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114209651-A | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof | 上海欣峰制药有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114053226-A | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof | 上海欣峰制药有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-2802670-B1 | LYSOSOMAL ENZYME ASSAY METHODS AND COMPOSITIONS | UNIV WASHINGTON (US) | 2019-12-25 | — | — | EP | disclosed |
| EP-2403447-B1 | MICROENCAPSULATED BIOACTIVE AGENTS FOR ORAL DELIVERY AND METHODS OF USE THEREOF | TAMARISK TECH GROUP LLC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180340174-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | NANOCORE APS (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2574669-B1 | BIOLOGICAL SAMPLE PRETREATMENT METHOD, METHOD FOR DETECTING RNA, AND PRETREATMENT KIT | DNAFORM KK (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20170159103-A1 | METHODS AND COMPOSITIONS FOR ASSAYING THE ACTIVITY OF ONE OR MORE LYSOSOMAL ENZYMES | UNIVERSITY OF WASHINGTON (US) | 2017-06-08 | — | — | US | disclosed |
| US-9518901-B2 | Pretreatment method of biological sample, detection method of RNA, and pretreatment kit | KABUSHIKI KAISHA DNAFORM (JP) | 2016-12-13 | — | — | US | disclosed |
| US-9512463-B2 | Methods and compositions for assaying the activity of one or more lysosomal enzymes | UNIVERSITY OF WASHINGTON (US) | 2016-12-06 | — | — | US | disclosed |
| WO-2004058179-A2 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004014322-A2 | IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003062461-A1 | FMDV LEADER PEPTIDASE ASSAY | AMURA THERPEUTICS LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| EP-1105148-A4 | ANALOGS OF UDP-MURNAC PEPTIDES, ASSAYS AND KITS | INCARA PHARMACEUTICALS CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20010049117-A1 | ANALOGS OF UDP-MURNAC PEPTIDES, ASSAYS, KITS AND RELATED METHODS OF THEIR USE | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2001-12-06 | — | — | US | disclosed |
| EP-1105148-A1 | ANALOGS OF UDP-MURNAC PEPTIDES, ASSAYS AND KITS | Incara Pharmaceuticals Corp. (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2001012142-A1 | METHODS FOR ASSAYING TRANSGLYCOSYLASE REACTIONS, AND FOR IDENTIFYING INHIBITORS THEREOF | IRL, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000010587-A1 | ANALOGS OF UDP-MURNAC PEPTIDES, ASSAYS AND KITS | INCARA PHARMACEUTICALS CORP. (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0601897-A1 | Method for the preparation of glycosylamines from reducing sugars | ERIDANIA BEGHIN-SAY (FR) | 1994-06-15 | — | — | EP | disclosed |